Summary of COVID-19 siltuximab studies

1. Declercq et al., Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

149 patient siltuximab late treatment RCT: 64% higher mortality (p=0.27).
RCT 342 hospitalized COVID-19 patients with hypoxia and signs of cytokine release syndrome in Belgium, showing no significant difference in time to clinical improvement, mortality, or other outcomes with IL-1 blockade (anakinra) or IL-6 blockade (siltuximab, tocilizumab) compared to standard of care.
Dec 2021, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260021003775, https://c19p.org/declercq

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0